Initial experience of the safety and tolerability of the BNT162b2 (Pfizer-Bio-N-Tech) vaccine in extremely vulnerable children aged 12–15 years
Authors:
Open Access
- 26 August 2021
- journal article
- letter
- Published by BMJ in Archives of Disease in Childhood
- Vol. 107 (2) , 205-207
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in AdolescentsNew England Journal of Medicine, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort studyBMJ, 2020
- Severe and fatal forms of COVID-19 in childrenArchives de Pédiatrie, 2020